SGLT2 Inhibitor Deal Benchmarks in Metabolic & Obesity

Median Upfront

$751M

Range: $413M - $1.1B

Total Deal Value

$3.6B

Range: $2.3B - $4.8B

Royalty Rate

15% - 27.5%

Tiered up to 31.5%

Dev Milestones

$506M

Range: $342M - $671M

Model Your Deal

Market Analysis

SGLT2 Inhibitor therapies in metabolic & obesity have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 sglt2 inhibitor asset in metabolic & obesity is $751M, with total deal values reaching $3.6B. Development milestones average $506M, while regulatory milestones contribute $618M.

The metabolic & obesity sglt2 inhibitor landscape is characterized by extremely high competitive intensity driven by the GLP-1 revolution and massive obesity market opportunity. Oral formulations, dual/triple incretins, and muscle-sparing approaches command unprecedented deal valuations. The recommended deal structure allocates approximately 21% to upfront payments and 79% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for sglt2 inhibitor metabolic & obesity deals range from 15% to 27.5% at the base tier, with tiered escalation reaching 19%-31.5% on blockbuster sales. Commercial milestones averaging $1.7B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a sglt2 inhibitor metabolic & obesity licensing deal?

Based on our analysis, Phase 2 sglt2 inhibitor licensing deals in metabolic & obesity average $751M in upfront payments, with a range of $413M to $1.1B depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for sglt2 inhibitor metabolic & obesity transactions?

The median total deal value for Phase 2 sglt2 inhibitor assets in metabolic & obesity is $3.6B, ranging from $2.3B to $4.8B. This includes development milestones ($506M), regulatory milestones ($618M), and commercial milestones ($1.7B).

What royalty rates are standard for sglt2 inhibitor deals in metabolic & obesity?

Base royalty rates for sglt2 inhibitor metabolic & obesity transactions range from 15% to 27.5%, with tiered escalations reaching 19%-31.5% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in sglt2 inhibitor metabolic & obesity deals?

SGLT2 Inhibitor metabolic & obesity deals allocate approximately 79% of total deal value to milestones. Development milestones ($506M) make up the largest share, followed by commercial milestones ($1.7B) and regulatory milestones ($618M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Metabolic & Obesity

View

GLP-1 Agonist in Metabolic & Obesity

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included